IDiyas

For the Inventor, By the Inventor

Foster City, CA, United States of America

Fang Wang

USPTO Granted Patents = 26 

 

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 130(Granted Patents)


Company Filing History:

goldMedal8 out of 919 
 
Gilead Sciences, Inc.
 patents
silverMedal8 out of 79 
 
Gilead Pharmasset LLC
 patents
bronzeMedal5 out of 16 
 
Gilead Calistoga LLC
 patents
4. 2 out of 4 
 
Sierra Oncology, Inc.
 patents
5. 2 out of 57 
 
Global Blood Therapeutics, Inc.
 patents
6. 1 out of 356 
 
Glaxosmithkline LLC
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
26 patents (USPTO):
1. 12473277 - Solid forms of a modulator of hemoglobin (2025-11-18),
2. RE50497 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2025-07-22),
3. 11851424 - Solid forms of a modulator of hemoglobin (2023-12-26),
4. RE49445 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2023-03-06),
5. 11203599 - Solid forms of an antiviral compound (2021-12-21),
6. RE48285 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2020-10-26),
7. 10730879 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2020-08-04),
8. 10604530 - Solid forms of an antiviral compound (2020-03-31),
9. 10442805 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2019-10-15),
10. 10202384 - Solid forms of a toll-like receptor modulator (2019-02-12),
11. 10155781 - Co-crystals, salts and solid forms of tenofovir alafenamide (2018-12-18),
12. 9884873 - Solid forms of an antiviral compound (2018-02-06),
13. 9809559 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2017-11-07),
14. 9777028 - Co-crystals, salts and solid forms of tenofovir alafenamide (2017-10-03),
15. 9708327 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2017-07-18),

Title: Innovations and Contributions of Fang Wang

Introduction

Fang Wang is an accomplished inventor based in Foster City, CA, with an impressive portfolio of 24 patents. His work primarily focuses on pharmaceutical innovations, which have significant implications in the healthcare sector.

Latest Patents

Among his latest patents, Fang Wang has made notable advancements with the development of solid forms of a modulator of hemoglobin. This includes the preparation and characterization of forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), as well as processes for manufacturing and methods of utilizing these forms. Additionally, he has contributed to the stability of novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide, tailored for pharmaceutical formulations and their therapeutic applications.

Career Highlights

Fang has gained substantial experience through his tenure at reputable companies such as Gilead Sciences, Inc. and Gilead Pharmasset LLC. His extensive research and development efforts have been directed towards enhancing pharmaceutical formulations and their therapeutic effectiveness.

Collaborations

Throughout his career, Fang Wang has partnered with prominent professionals such as Bing Shi and Ernest A. Carra. These collaborations have contributed to the innovative solutions and advancements in the pharmaceutical domain that he is known for today.

Conclusion

Fang Wang's contributions to the field of pharmaceuticals, marked by his numerous patents and collaborations, underscore his dedication to advancing medical science. His work not only enhances understanding in the field but also showcases the impact of innovation in creating effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…